This week in therapeutics




Licensing status

Publication and contact information



IL-1b; IL-1 receptor; IL-17A

Mouse studies suggest inhibiting IL-1b signaling could help treat obesity-associated asthma. In obese mice, levels of IL-1b-expressing macrophages in adipose tissue and the lungs were greater than those in nonobese animals. IL-1b-expressing macrophages increased airway hyperreactivity and numbers of Il-17a-producing cells in the lungs. Also in the obese mice, an IL-1 receptor antagonist decreased airway hyperreactivity and numbers of Il-17a-producing cells in the lungs compared with no treatment. Future studies could include testing anti-IL-1b antibodies in obese mice.
Swedish Orphan Biovitrum AB markets Kineret anakinra, an IL-1 receptor antagonist, to treat rheumatoid arthritis (RA) and cryopyrin-associated periodic syndrome (CAPS).
Bristol-Myers Squibb Co. and Novartis AG market Ilaris canakinumab (ACZ885), a human anti-IL-1b mAb, to treat CAPS. Bristol-Myers also markets the mAb to treat hyperuricemia and gout.
These companies and several others have compounds targeting IL-1 receptor, IL-1b and IL-17A in Phase III and earlier testing for multiple indications including asthma.

SciBX 7(4); doi:10.1038/scibx.2014.119
Published online Jan. 30, 2014

Patent and licensing status unavailable

Kim, H.Y. et al. Nat Med.; published online Dec. 15, 2013;
Contact: Dale T. Umetsu, Harvard Medical School, Boston, Mass.